ERBB2 and breast carcinoma: The estrogen receptor (ER), the progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are the molecular biomarkers currently used in routine clinical practice to help make treatment decisions for breast cancer [3].